Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
Source ↗
👁 0
💬 0
Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer immunotherapy.
The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Ventures, the EIB, and Neva SGR (Intesa Sanpaolo Group). Existing investors, 5AM Ventures, And
The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Ventures, the EIB, and Neva SGR (Intesa Sanpaolo Group). Existing investors, 5AM Ventures, And
Comments (0)